Clinical trials: Idiopathic Interstitial Pneumonias
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
To evaluate the efficacy and safety of 26-weeks of treatment with riociguat vs. placebo in patients with symptomatic PH (pulmonary hypertension) associated with IIP (idiopathic interstitial pneumonias).
- Trial name
- RISE-IIP (NCT02138825)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 93 sites in United States, Argentina and 19 more
- Volunteers
- 147 people
- Sponsor
- Bayer
Pulmonary Fibrosis
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of…
- Trial name
- NCT04308681
- Testing
- BMS-986278
- Where
- 119 sites in United States, Argentina and 16 more
- Volunteers
- 403 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
Study of ORJ-001 for the Treatment of IPF
ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by…
- Trial name
- NCT07869147
- Testing
- ORJ-001
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Oorja Bio, Inc.
Diopathic Pulmonary Fibrosis, Pulmonary Fibrosis
The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.
The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetic profiles of SC1011,in health conditions.
- Trial name
- NCT06160440
- Testing
- SC1011
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Idiopathic Pulmonary Fibrosis, Fibrosis
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK), quality of life and exploratory pharmacodynamics (PD) of two treatment…
- Conditions
- Idiopathic Pulmonary Fibrosis, Fibrosis, Idiopathic Interstitial Pneumonias, Pathologic Processes
- Trial name
- NCT03142191
- Testing
- CC-90001
- Where
- 112 sites in United States, Australia and 11 more
- Volunteers
- 138 people
- Sponsor
- Celgene
Idiopathic Pulmonary Fibrosis
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary…
- Trial name
- NCT04419558
- Testing
- Pamrevlumab
- Where
- 157 sites in United States, Argentina and 23 more
- Volunteers
- 372 people
- Sponsor
- Kyntra Bio
Idiopathic Pulmonary Fibrosis
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of QAX576 in patients with idiopathic pulmonary fibrosis.
- Trial name
- NCT01266135
- Testing
- QAX576
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Idiopathic Pulmonary Fibrosis
Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
To evaluate the safety and tolerability of pamrevlumab in participants with IPF, and the efficacy of pamrevlumab in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these participants.
- Trial name
- NCT01890265
- Testing
- Pamrevlumab, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
- Where
- 42 sites in United States, Australia and 5 more
- Volunteers
- 160 people
- Sponsor
- Kyntra Bio
Idiopathic Pulmonary Fibrosis
A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
This Phase 2 study is to be conducted to evaluate the safety, tolerability, and activity of 400 mg of belumosudil orally (PO) once-daily (QD) compared to Best Supportive Care (BSC) in male and postmenopausal/surgically sterilized…
- Trial name
- NCT02688647
- Testing
- Belumosudil, BSC
- Where
- 10 sites in United States
- Volunteers
- 76 people
- Sponsor
- Kadmon Corporation, LLC
Pulmonary Alveolar Proteinosis, COPD
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality.
- Conditions
- Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia
- Trial name
- GARM-COVID19 (NCT04326036)
- Testing
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Black Tie Medical, Inc.
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
- Trial name
- NCT02036970
- Testing
- Bardoxolone methyl
- Where
- 32 sites in United States, Germany
- Volunteers
- 166 people
- Sponsor
- Biogen
Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension
This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks…
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
- Trial name
- NCT07613216
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cosmos Rx, Inc
Idiopathic Pulmonary Fibrosis
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with IPF.
- Trial name
- NCT03955146
- Testing
- Pamrevlumab
- Where
- 125 sites in United States, Argentina and 7 more
- Volunteers
- 393 people
- Sponsor
- Kyntra Bio